Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: Comparison of plasma and urine kinetics

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 2, 1999, Pages 119-125

  Gurumurthy, P ^a,c   Ramachandran, G ^a   Vijayalakshmi, S ^a   Kumar, A K Hemanth ^a   Venkatesan, P ^a   Chandrasekaran, V ^a   Vjayasekaran, V ^b   Kumaraswami, V ^a   Prabhakar, R ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b Chennai Medical College   (India)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Anti tuberculosis drugs; Bioavailability; Plasma; Urine

Indexed keywords

DRUG METABOLITE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFATER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; INDIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUBERCULOSIS; URINARY EXCRETION;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMBINATIONS; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; RIFAMPIN;

EID: 0033061751     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mitchison D A. Basic mechanisms of chemotherapy. Chest 1979; 76 (Suppl): 771-781.
2. Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981; 75: 331-357.
3. Gruppo Lepetit. Rifater 125 SCT for intermittent use. Summary of chemistry and pharmacy information.
4. Acocella G, Mattiussi R, Segre G. Multi compartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl rifampicin in subjects treated for one week. Pharmacol Rev Commun 1978; 10: 271-288.
5. Acocella G, Conti R, Luisetti M, Pozzi E, Grassi C. Pharmacokinetic studies on antituberculosis regimens in humans. 1) Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study. Am Rev Respir Dis 1985; 132: 510-515.
6. Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampicin and pyrazinamide administered in free combination and in a fixed triple designed for daily use in antituberculosis chemotherapy - 1. Single-dose study. Am Rev Respir Dis 1988; 138: 882-885.
7. Acocella G, Luisetti M, Gialdroni Grassi, Peona V, Pozzi E, Grassi C. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed triple formulation) in intermittent antituberculosis chemotherapy. Monaldi Arch Chest Dis 1993; 48: 205-209.
8. Ellard G R, Ellard D R, Allen B W, et al. The bioavailability of isoniazid, rifampicin and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133: 1076-1080.
9. Aspesi F. Dissolution testing. Satellite symposium on quality control of antituberculosis drugs. Bull Int Union Tuberc Lung Dis 1989; 64 (1): 37-38.
10. Immanuel C, Jayasankar K, Narayana A S L, Raghupati Sarma G. Self induction of rifampicin metabolism in man. Ind J Med Res 1985; 82: 381-387.
11. Dickinson J M, Aber V R, Allen B W, Ellard G A, Mitchison D A. Assay of rifampicin in serum. J Clin Pathol 1974; 27: 452-462.
12. Olson W A, Dayton P G, Israilli Z H, Pruitt A W. Spectrophotofluorimetric assay for isoniazid and acetylisoniazid in plasma adapted to paediatric studies. Clin Chem 1977; 23: 745-748.
13. Gurumurthy P, Nair N G K, Raghupati Sarma G. Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids. Ind J Med Res 1980; 71: 129-134.
14. Sunahara S, Nakagawa H. Metabolic study and controlled clinical trials of rifampicin. Chest 1972; 61: 526-532.
15. Ellard G A, Gammon P T. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4: 83-113.
16. Brod J, Sirota J H. J Clin Invest 1948; 27: 645.
17. Acocella G, Angel J H. Short-course chemotherapy of pulmonary tuberculosis. A new approach to drug dosages in the initial intensive phase. Am Rev Respir Dis 1986; 134: 1285-1286.
18. Gurumurthy P, Immanuel C, Ramachandran G, et al. Pharmacokinetics of rifampicin, ethambutol, isoniazid and pyrazinamide following administration of the drugs individually or in different combinations to healthy volunteers. (In press)